Detalhe da pesquisa
1.
Genomic correlates of clinical outcome in advanced prostate cancer.
Proc Natl Acad Sci U S A
; 116(23): 11428-11436, 2019 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31061129
2.
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.
Radiology
; 265(2): 426-36, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22891356
3.
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Clin Cancer Res
; 15(2): 723-30, 2009 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19147780
4.
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
Clin Cancer Res
; 14(3): 804-10, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18245542
5.
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
Clin Cancer Res
; 14(21): 7127-37, 2008 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18981012
6.
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
Clin Cancer Res
; 12(17): 5207-15, 2006 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16951240
7.
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.
Clin Cancer Res
; 16(11): 3067-77, 2010 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20484020
8.
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.
Mol Cancer Ther
; 8(6): 1430-7, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19509256
9.
Reovirus therapy in cancer: has the orphan virus found a home?
Expert Opin Investig Drugs
; 17(12): 1925-35, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19012507